Evaluation of the Abuse Potential of Novel Amphetamine Derivatives with Modifications on the Amine (NBNA) and Phenyl (EDA, PMEA, 2-APN) Sites

다국어 초록 (Multilingual Abstract)

Recently, there has been a rise in the number of amphetamine derivatives that serve as substitutes for controlled substances (e.g. amphetamine and methamphetamine) on the global illegal drug market. These substances are capable of producing rewarding effects similar to their parent drug. In anticipation of the future rise of new and similar psychoactive substances, we designed and synthesized four novel amphetamine derivatives with N-benzyl, N-benzylamphetamine HCl (NBNA) substituent on the amine region, 1,4-dioxane ring, ethylenedioxy-amphetamine HCl (EDA), methyl, para-methylamphetamine HCl (PMEA), and naphthalene, 2-(aminopropyl) naphthalene HCl (2-APN) substituents on the phenyl site. Then, we evaluated their abuse potential in the conditioned place preference (CPP) test in mice and self-administration (SA) test in rats. We also investigated the psychostimulant properties of the novel drugs using the locomotor sensitization test in mice. Moreover, we performed qRT-PCR analyses to explore the effects of the novel drugs on the expression of D1 and D2 dopamine receptor genes in the striatum. NBNA, but not EDA, PMEA, and 2-APN, induced CPP and SA in rodents. None of the test drugs have produced locomotor sensitization. qRT-PCR analyses demonstrated that NBNA increased the expression of striatal D1 dopamine receptor genes. These data indicate that NBNA yields rewarding effects, suggesting potential for abuse. Continual observation for the rise of related substances is thus strongly encouraged.

참고문헌 (Reference)

1 Moore, K. A., "α-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine" 39 : 83-89, 1995

2 United Nations Office on Drugs and Crime, "World Drug Report 2016" United Nations publication

3 Ali, R., "WHO multi-site project on methamphetamine induced psychosis: a descriptive report on findings from participating countries" Drug & Alcohol Services South Australia 2006

4 Kalant, H., "The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs" 165 : 917-928, 2001

5 McPherson, C. S., "The nuclear transcription factor CREB: involvement in addiction, deletion models and looking forward" 5 : 202-212, 2007

6 Schatzberg, A. F., "The American Psychiatric Publishing Textbook Of Psychopharmacology" American Psychiatric Pub 2009

7 Halberstadt, A. L., "Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice" 70 : 218-227, 2013

8 Funada, M., "Rewarding effects of N-methyl-1-(4-Methoxyphenyl)-2-aminopropane (PMMA) in mice: role of modifications of dopamine system mediated through its monoamine oxidase inhibition" 5 : 172-, 2014

9 Marona-Lewicka, D., "Reinforcing effects of certain serotonin-releasing amphetamine derivatives" 53 : 99-105, 1996

10 de la Peña, J. B., "Pre-exposure to related substances induced place preference and self-administration of the NMDA receptor antagonist-benzodiazepine combination, zoletil" 24 : 20-28, 2013

11 Berman, S. M., "Potential adverse effects of amphetamine treatment on brain and behavior: a review" 14 : 123-142, 2009

12 Tettey, J., "Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for Asia and the Pacific" Global SMART Programme 1-162, 2013

13 Thanos, P. K., "Overexpression of dopamine D2 receptors reduces alcohol self-administration" 78 : 1094-1103, 2001

14 Cain, M. E., "Individual differences in amphetamine self-administration: The role of the central nucleus of the amygdala" 33 : 1149-1161, 2008

15 Vallejos, G., "Heteroarylisopropylamines as MAO inhibitors" 13 : 4450-4457, 2005

16 Flomenbaum, N. E., "Goldfrank’s Toxicologic Emergencies" McGraw Hill 2006

17 Drug Enforcement Administration, "Drugs of Abuse: 2011 Edition. A DEA Resource Guide"

18 Lüscher, C., "Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling" 69 : 650-663, 2011

19 Kim, J. Y., "Determination of amphetamine-type stimulants, ketamine and metabolites in fingernails by gas chromatography-mass spectrometry" 194 : 108-114, 2010

20 Kang, S., "D1 receptor-mediated inhibition of medial prefrontal cortex neurons is disrupted in adult rats exposed to amphetamine in adolescence" 324 : 40-49, 2016

21 Robaa, D., "Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives" 54 : 7422-7426, 2011

22 Salomon, L., "Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons" 103 : 7476-7481, 2006

23 Sitte, H. H., "Amphetamines, new psychoactive drugs and the monoamine transporter cycle" 36 : 41-50, 2015

24 United Nations Office on Drugs and Crime, "Amphetamines and ecstasy. 2011 Global ATS Assessment" United Nations Publication

25 Berman, S., "Abuse of amphetamines and structural abnormalities in the brain" 1141 : 195-220, 2008

26 Taniguchi, M., "A technique combining trifluoroacetyl derivatization and gas chromatography-mass spectrometry to distinguish methamphetamine and its 4-substituted analogs" 45 : 1473-1476, 2010

27 Matsumoto, T., "5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis" 24 : 1362-1370, 2014

28 Dean, B. V., "2C or not 2C: phenethylamine designer drug review" 9 : 172-178, 2013